Invivyd 

$0.8144
151
-$0.02-2.47% 19:40 Today

Statistics

Day High
0.82
Day Low
0.7901
52W High
3.07
52W Low
0.528
Volume
1,527,757
Avg. Volume
4,801,503
Mkt Cap
240.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.2
-0.13
-0.07
-0
Expected EPS
-0.133333
Actual EPS
N/A

Financials

-98.25%Profit Margin
Unprofitable
2021
2022
2023
2024
2025
53.43MRevenue
-52.49MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IVVD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the development of monoclonal antibodies for the treatment of various diseases, similar to Invivyd's focus on antibody therapies.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is involved in the research and development of antiviral drugs, directly competing with Invivyd's efforts in infectious disease treatments.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca competes with Invivyd in the development of treatments for infections and diseases, including their work on vaccines and antibody therapies.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a direct competitor in the pharmaceutical and biotechnology industry, with a broad portfolio that includes treatments for infectious diseases, competing with Invivyd's focus.
Merck
MRK
Mkt Cap366B
Merck & Co. is involved in the creation of vaccines and therapeutic antibodies, competing with Invivyd in the infectious disease space.
Abbott Laboratories
ABT
Mkt Cap194.62B
Abbott Laboratories competes with Invivyd through its diagnostic and medical devices for infectious diseases, as well as its pharmaceutical products.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for infectious diseases, which puts it in competition with Invivyd's therapeutic development.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in the biopharmaceutical field, focusing on innovative medicines that include infectious disease treatments, similar to Invivyd's focus.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of drugs for infectious diseases, directly competing with Invivyd.
Sanofi
SNY
Mkt Cap107.39B
Sanofi competes with Invivyd in the global healthcare market, particularly in the development of vaccines and treatments for infectious diseases.

About

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Show more...
CEO
William E. Duke Jr.
Employees
122
Country
United States
ISIN
US00534A1025

Listings

0 Comments

Share your thoughts

FAQ

What is Invivyd stock price today?
The current price of IVVD is $0.81 USD — it has decreased by -2.47% in the past 24 hours. Watch Invivyd stock price performance more closely on the chart.
What is Invivyd stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Invivyd stocks are traded under the ticker IVVD.
Is Invivyd stock price growing?
IVVD stock has fallen by -16.36% compared to the previous week, the month change is a +40.86% rise, over the last year Invivyd has showed a -19.13% decrease.
What is Invivyd market cap?
Today Invivyd has the market capitalization of 240.05M
When is the next Invivyd earnings date?
Invivyd is going to release the next earnings report on November 05, 2026.
What were Invivyd earnings last quarter?
IVVD earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.11 USD resulting in a -31.25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Invivyd revenue for the last year?
Invivyd revenue for the last year amounts to 53.43M USD.
What is Invivyd net income for the last year?
IVVD net income for the last year is -52.49M USD.
How many employees does Invivyd have?
As of September 04, 2026, the company has 122 employees.
In which sector is Invivyd located?
Invivyd operates in the Health & Wellness sector.
When did Invivyd complete a stock split?
Invivyd has not had any recent stock splits.
Where is Invivyd headquartered?
Invivyd is headquartered in NEW HAVEN, United States.